Fc Protein and Glycoengineered Antibodies Market – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

1. Fc Protein and Glycoengineered Antibodies Fc Protein and Glycoengineered Antibodies Market – Size, Share, Outlook, and Opportunity Market – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027 Analysis, 2019 – 2027 Monoclonal antibodies are developed by identical immune cells, which have a therapeutic use. The crystallized fragments (Fc) protein and glycoengineered antibodies are known as the next generation antibodies. These monoclonal antibodies are immunoglobulin G (IgG) type of molecules, which are attached to a glycan residue on crystallisable fragment. Glycoengineering is the method by which these antibodies are created. They have varied applications for the treatment of diseases such as multiple sclerosis and cancers. Request Sample Copy of Research Report @ Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2626 https://www.coherentmarketinsights.com/insight/request-sample/2626 Global Fc Protein and Glycoengineered Antibodies Market Drivers Global Fc Protein and Glycoengineered Antibodies Market Drivers Key players in the market are focusing on research and development activities and receiving approvals from regulatory bodies, which are expected to boost the global Fc protein and glycoengineered antibodies market growth over the forecast period. For instance, in 2016, Genentech Inc. received approval from the U.S. Food and drug Administration (U.S. FDA) for Tecentriq (Atezolizumab). It is being used for the treatment of urothelial carcinoma. In March 2019, Tecentriq received its second approval from the U.S. FDA for the treatment of small lung cancer. Furthermore, in November 2017, TG Therapeutics, Inc. began its clinical trial of Ublituximab for the treatment of multiple sclerosis. It is currently in third phase of its clinical trial. Factors such as increasing product approvals and robust pipeline are expected to drive the global fc protein and glycoengineered antibodies market growth. Increasing prevalence of diseases such as cancer is expected to propel the global Fc protein and glycoengineered antibodies market growth. According to the World Health Organization (WHO), cancer is considered as the second most leading cause of death worldwide, and, in 2018, around 9.6 million people died worldwide due to cancer. Hence, glycoengineered antibodies can be developed for the treatment of cancer and thus, this factor is expected to drive growth of the global fc protein and glycoengineered antibodies market over the forecast period.

2. Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Fc Protein and Glycoengineered Antibodies Market Research Objective and Assumption • Fc Protein and Glycoengineered Antibodies Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Fc Protein and Glycoengineered Antibodies Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Fc Protein and Glycoengineered Antibodies Market, By Regions • Fc Protein and Glycoengineered Antibodies Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Fc Protein and Glycoengineered Antibodies Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Fc Protein and Glycoengineered Antibodies Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Fc Protein and Glycoengineered Antibodies Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Global Fc Protein and Glycoengineered Antibodies Market Restraints Global Fc Protein and Glycoengineered Antibodies Market Restraints High cost of drugs is expected to hinder the global Fc protein and glycoengineered antibodies market growth. Manufacturers are focused on offering a highly effective drug, thus investing more into research and development activities. This increases the final cost price of the product. According to Pharmacy and Healthcare Communication, LLC, Gazyva costs around US$ 41,300 for six months treatment of cancer. Hence, this factor is expected to restrain growth of the global fc protein and glycoengineered antibodies market. Global Fc Protein and Glycoengineered Antibodies Market Regional Analysis Global Fc Protein and Glycoengineered Antibodies Market Regional Analysis North America region is expected to dominate in the global fc protein and glycoengineered antibodies market due to factors such as product launches, presence of leading manufacturers (such as F. Hoffmann La-Roche Ltd.), and active research and development in the field. Drugs

3. such as Obinutuzumab (Gazyva), Mogamulizumab (Poteligeo), Atezolizumab (Tecentriq), and Durvalumab (Imfinzi) have been approved in the U.S. in 2013, 2018, 2016, and 2017 respectively. Europe is expected to witness significant growth in the global Fc protein and glycoengineered antibodies market. Factors such as approval for new drugs is expected to drive the Europe’s Fc protein and glycoengineered antibodies market growth over the forecast period. For instance, in 2018, Kyowa Hakko Kirin Co. Ltd. received an approval from the European Commission to market the Poteligeo antibody in the European market. It is the first biological product that is being directed against chemokine receptor 4 (CCR4), which will be used for the treatment of Sezary syndrome that has been previously treated by systemic therapy. Such new drug approvals are expected to propel Europe Fc protein and glycoengineered antibodies market growth over the forecast period. Global Fc Protein and Glycoengineered Antibodies Market Key Players Global Fc Protein and Glycoengineered Antibodies Market Key Players Some of the major players operating in the global Fc protein and glycoengineered antibodies market include Kyowa Hakko Kirin Co. Ltd., Merck KGaA, Boehringer Ingelheim International GmbH, AstraZeneca Plc, Amgen Inc., Genentech Inc., Five Prime Therapeutics Inc., Celldex Therapeutics, Clovis Oncology, and TG Therapeutics, Inc. Request For Customization of Research Report @ Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2626 https://www.coherentmarketinsights.com/insight/request-customization/2626 About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: Email: sales@coherentmarketinsights.com sales@coherentmarketinsights.com